Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604

Clin Gastroenterol Hepatol. 2009 Nov;7(11):1257. doi: 10.1016/j.cgh.2009.09.016. Epub 2009 Sep 22.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab

Substances

  • Antibodies, Monoclonal
  • Immunologic Factors
  • Infliximab